Ovarian hormone therapy

Ovarian hormone therapy includes all pharmacological interventions that use estrogens, progestogens, combined estrogen and progestogen regimens and, for highly selected indications, other sex hormones to replace, modulate or rebalance ovarian endocrine function in the different clinical settings in which endogenous hormone production is absent, reduced, fluctuating or inadequately synchronized with the body’s needs. The core of this field is represented by estradiol replacement and progestogen protection in hypoestrogenic conditions, particularly premature ovarian insufficiency and the symptomatic menopausal transition, but the same endocrine rationale extends to the management of more complex conditions such as iatrogenic hypoestrogenism, the need for endometrial protection, selection among different routes of administration, treatment of genitourinary symptoms and rigorous assessment of additional therapies in selected subgroups.

The objective is not simply to administer hormones, but to reconstruct a biological signal that is consistent with the ovarian physiology that has been lost or altered, taking into account the timing of intervention, the presence or absence of the uterus, thromboembolic and oncological risk profiles, the pharmacokinetics of the available formulations, quality of life, bone and cardiovascular health and the continuous balance between clinical benefit and potential iatrogenic harm. The principles described here constitute the common foundation that makes clinical practice rational, from the initial prescription to long term follow up, and explain why ovarian hormone therapy should be regarded as a true form of precision endocrine medicine.

Ovarian hormone therapy is based on the fact that the ovary does not produce a single hormone, but generates a complex, pulsatile and dynamic endocrine signal, centered mainly on estradiol and progesterone, with smaller but biologically relevant contributions from ovarian androgens and peripheral metabolites. Estradiol regulates maturation of target tissues, vasomotor homeostasis, genitourinary trophism, bone metabolism, neurocognitive function and numerous aspects of cardiovascular and metabolic physiology. Progesterone, in turn, is not simply a complement to estrogen, but the principal regulator of the secretory phase of the endometrium and of the balance between endometrial proliferation and differentiation. When ovarian function is lost or becomes inadequate, the consequence is therefore not merely loss of menstrual cyclicity, but disruption of a widespread regulatory system involving numerous organs and functions.

This leads to the first major objective of therapy, namely to replace hormone deficiency when the deficiency is pathological or occurs earlier than expected in the normal biological course, as in premature ovarian insufficiency, hypogonadotropic hypoestrogenism or iatrogenic forms caused by surgery, chemotherapy or radiotherapy. In these settings, the rationale is genuinely one of replacement, because the aim is to restore estrogen exposure that is as close as possible to that of a woman of reproductive age, not only to relieve symptoms such as hot flashes, insomnia, vaginal dryness or reduced quality of life, but also to reduce the long term effects of estrogen deprivation on bone, the cardiovascular system, sexual function and general health.

A second objective is the modulation of the menopausal transition and symptomatic postmenopause. In this case, the aim is not to restore full ovarian function, but to reduce the clinical impact of its progressive cessation during a stage of life in which the benefit to risk balance depends substantially on age, time since menopause, the individual risk profile and the nature of the symptoms. In this setting, hormone therapy is the most effective treatment for vasomotor symptoms and an important intervention for urogenital trophism and prevention of bone loss, but it requires closer personalization than clearly replacement based treatment in a younger woman with pathological hypoestrogenism.

There is also a third objective, which is less intuitive but equally important, namely endometrial protection. Estrogen administered when the uterus is present stimulates endometrial proliferation. If this proliferation remains unopposed by adequate progestogen exposure, the risk of hyperplasia and neoplastic transformation increases. Ovarian hormone therapy therefore cannot be regarded simply as the choice of an estrogen, but must be constructed as a combined regimen that is consistent with the anatomy and biological risk of the patient. In summary, ovarian hormone therapy has three interconnected targets: restoring estrogen signaling when it is deficient, treating the symptoms and systemic effects of ovarian decline when indicated, and ensuring that endocrine reconstruction is safe for the endometrium and other target organs.

The estrogens used in clinical practice are not pharmacologically equivalent. The agent most closely resembling ovarian physiology is estradiol, which is available in oral, transdermal, gel, spray and vaginal formulations, the latter being used primarily for local treatment. The route of administration substantially changes the pharmacokinetic profile. Oral administration involves intestinal absorption and hepatic first pass metabolism, with more pronounced effects on hepatic synthesis of binding proteins, coagulation factors, triglycerides and other metabolic mediators. The transdermal route avoids hepatic first pass metabolism and produces more stable concentrations, with less effect on the coagulation cascade and often better tolerability in patients with metabolic or thrombotic risk.

The progestogen component is also more complex than it may appear. Endometrial protection can be achieved with micronized progesterone or with synthetic progestogens that differ in potency, androgenic, glucocorticoid or mineralocorticoid activity and tolerability profile. The choice is not neutral, because it affects not only bleeding control and endometrial safety, but also breast tenderness, fluid retention, mood, drowsiness, metabolic profile and overall acceptability of the treatment regimen. In addition, when higher estrogen doses are used, the progestogen component must be adequately proportioned, because insufficient endometrial protection transforms an apparently correct treatment into a biologically incomplete one.

Regimens may be sequential or continuous. In sequential regimens, estrogen is administered continuously and a progestogen is added for a defined part of the cycle, producing withdrawal bleeding. In continuous combined regimens, estrogen and progestogen are taken together every day with the aim of achieving amenorrhea and symptom stability after the initial adjustment phase. The choice depends on age, clinical stage, patient preference, the presence of residual ovarian activity, tolerance of bleeding and the general endocrine context. In women with premature ovarian insufficiency who wish to preserve the possibility of spontaneous conception, a sequential regimen may be more physiologically appropriate because it does not interfere with possible intermittent residual ovulation.

Vaginal formulations represent a separate category. Low dose local vaginal estrogen, together with other options for treatment of genitourinary syndrome of menopause, has a different purpose from systemic therapy. Its objective is not to reconstruct the entire ovarian signal, but to selectively correct urogenital trophic deficiency. Pharmacology in this setting is directed toward maximum local efficacy with minimal systemic exposure. Low dose vaginal therapy should therefore not be conceptually confused with systemic therapy, even though both belong to the broader field of ovarian hormone therapy. Once again, there is no single treatment, but several pharmacological structures designed around different clinical objectives.

Initiating ovarian hormone therapy first requires clarification of the problem being treated. A woman with premature ovarian insufficiency, a patient in perimenopause with severe vasomotor symptoms, a woman with early surgical menopause and a patient with isolated genitourinary symptoms do not require the same intensity of replacement or the same regimen. In pathological hypoestrogenism occurring at a young age, the rationale is to approach more complete replacement estrogen exposure, because the target is not only symptom relief, but also prevention of the systemic effects of prolonged deficiency. In menopause occurring at the usual age, the dose is instead constructed around the lowest level that effectively controls symptoms, with periodic reassessment of the benefit to risk balance.

The choice of starting dose should take into account the severity of hypoestrogenism, the speed of onset of the deficiency, age, cardiovascular and thromboembolic risk, the presence of the uterus, a history of endometriosis, body weight, liver comorbidity and the preferred route of administration. In younger women with premature ovarian insufficiency, recent guidelines often indicate the need for estrogen doses that are not minimal, but genuinely replacement doses capable of supporting bone and systemic health. In conventional menopausal settings, it is instead reasonable to begin with low or intermediate doses and titrate according to clinical response. The same molecule, for example transdermal estradiol, may therefore have a profoundly different biological meaning depending on the stage of life in which it is prescribed.

The presence of the uterus then requires selection of the progestogen regimen. When the uterus is present, systemic estrogen must be accompanied by adequate endometrial protection, apart from particular situations involving very low dose vaginal therapy with a local purpose. The choice between a sequential and continuous regimen depends on the context. In patients undergoing the menopausal transition or with possible residual ovarian activity, a sequential regimen may be more appropriate. In established postmenopause, a continuous combined regimen reduces bleeding and simplifies adherence. In women who have undergone hysterectomy, estrogen may be administered alone, except in particular settings such as a history of endometriosis, in which residual ectopic tissue may make it prudent to retain a progestogen component.

Finally, initiating treatment means already planning its titration. Systemic estrogen should not be modified impulsively in response to symptom fluctuations lasting only a few days, because target tissue response, neurovegetative readjustment and stabilization of the bleeding pattern require time. A well designed initial regimen reduces the need for frequent changes and begins with an essential question: what hormonal profile am I trying to reconstruct in this particular patient? Only when this question is clear can the dose, route, regimen and rhythm of follow up be selected with endocrine consistency.

Monitoring ovarian hormone therapy cannot be based on a single universal test, because the decisive parameter changes according to the therapeutic objective. In women treated for menopausal symptoms, the principal indicator of efficacy is improvement in hot flashes, sleep, quality of life, vaginal dryness, pain during intercourse, mood and overall functional stability. In premature ovarian insufficiency or pathological hypoestrogenism, monitoring must be broader and include bone health, cardiovascular profile, sexual quality of life, bleeding pattern, persistence of estrogen deficiency symptoms and the adequacy of the regimen for long term prevention.

Laboratory tests have a selective and context dependent role. Treatment is not routinely titrated to pursue an isolated estradiol value in every patient, because the relationship between serum concentration, tissue exposure and clinical benefit is not linear in the same way as in certain other endocrine axes. However, in specific situations, such as premature ovarian insufficiency, suspected inadequate replacement, unexpectedly poor clinical response, use of high dose transdermal formulations or suspected malabsorption of oral treatment, estradiol measurement may help determine whether systemic exposure is plausibly adequate. Even more important is monitoring clinical effect and the internal consistency of the therapeutic regimen.

In women with premature ovarian insufficiency, guidelines recommend assessment of bone mineral density at diagnosis and subsequent evaluations according to individual risk, particularly when treatment was started late, adherence is poor or osteopenia or osteoporosis is already present. Cardiovascular risk should also be reassessed periodically, because hormone therapy does not replace general preventive measures and does not independently neutralize all the effects of early ovarian loss. In physiological menopause, follow up should primarily verify persistence of the indication, the appearance of adverse events, the quality of symptom control and the appropriateness of continuing, reducing or discontinuing treatment.

Uterine bleeding plays a central role in monitoring. Spotting or irregular bleeding may occur during the first months of combined therapy, but its significance changes with time, type of regimen and patient profile. Persistent, late or atypical unscheduled bleeding always requires clinical and possibly instrumental reassessment, because symptom control cannot be achieved at the cost of inadequate endometrial surveillance. Ultimately, monitoring ovarian hormone therapy means verifying three things together: that clinical benefit is present, that biological safety is maintained and that treatment remains indicated in the patient’s actual clinical context.

The response to ovarian hormone therapy depends not only on the prescribed dose, but on the amount of hormone that consistently reaches target tissues and on how that exposure interacts with age, adiposity, liver function, enzymatic activity, the microbiota, concomitant medications and preexisting gynecological conditions. Variability of response is therefore intrinsic and should not be interpreted as failure of the treatment itself. The clearest example is the difference between oral and transdermal administration. The former is more susceptible to interference from hepatic metabolism and changes in protein synthesis, whereas the latter provides more linear and often more predictable pharmacokinetics in patients with thrombotic risk or hypertriglyceridemia.

Contraindications to systemic therapy must be assessed rigorously. A personal history of breast cancer, a recent or unexplained thromboembolic event, active liver disease, unexplained genital bleeding or an estrogen sensitive disorder that has not yet been fully characterized requires caution or contraindicates systemic treatment, apart from very rare exceptions managed in highly specialized settings. Even when treatment is not formally prohibited, the risks of venous thromboembolism, stroke or cardiovascular complications must be considered according to age, time since menopause, smoking, obesity, immobilization, known thrombophilia and the overall metabolic profile. In these situations, choosing the transdermal route may reduce risk, but does not remove the need for personalized assessment.

Gynecological history further modifies the situation. In women with previous endometriosis, estrogen therapy should not be prescribed mechanically, because residual endometriotic tissue may theoretically be reactivated by estrogen exposure that is not adequately opposed. Similarly, fibroids, adenomyosis or a particular tendency toward bleeding may influence the choice of regimen and route. Guidelines for premature ovarian insufficiency also emphasize that replacement therapy is not contraceptive. In women with intermittent residual ovarian activity, prescribing treatment must therefore clearly distinguish the replacement objective from any need for contraception.

A specific issue concerns so called compounded or nonstandardized bioidentical products. The problem is not terminology, but pharmacology and regulation. Preparations that are not subject to the same standards of quality control, dosing and safety as authorized products introduce variability that is difficult to measure and reduce the predictability of the clinical response. In a therapy that must by definition be precise, reproducible and monitorable, the use of insufficiently standardized preparations weakens the methodological basis of care. In endocrinology, biological stability also depends on the stability of the product used.

Ovarian hormone therapy has a different meaning in the various stages of reproductive and postreproductive life. In premature ovarian insufficiency, treatment is primarily replacement therapy. In these patients, the objective is not only to relieve symptoms, but to reduce the systemic consequences of menopause occurring many years before the physiological age. Current international guidelines recommend hormone therapy until the average age of natural menopause, even in the absence of marked vasomotor symptoms, specifically because of its role in protecting bone, cardiovascular and general health. This is one of the settings in which waiting for symptoms is endocrinologically inadequate.

In symptomatic postmenopause, the rationale is different. Treatment should be offered particularly when vasomotor symptoms, sleep disturbance or genitourinary syndrome of menopause impair quality of life and the benefit to risk balance is favorable. In younger women or during the first years after menopause, the benefit to risk profile is generally more favorable than in women who begin treatment many years later. Time since the final menstrual period is therefore not merely a chronological detail, but a biological determinant of the cardiovascular and thrombotic risk associated with systemic therapy.

In surgical or iatrogenic menopause occurring at a young age, the hormonal decline is abrupt and often more symptomatic than physiological menopause. Hormone therapy has a particularly important role in this setting, because sudden loss of ovarian function causes intense estrogen deprivation over a short period. However, the oncological context or the reason for surgery may profoundly alter the available therapeutic options. After risk reducing salpingo oophorectomy in women with BRCA mutations and no personal history of breast cancer, therapy may be considered until the age of natural menopause. After hormone sensitive cancers, any decision, when exceptionally considered, instead requires shared assessment with the oncology team.

There are also special settings in which the predominant symptom is not systemic, but urogenital. In women with isolated GSM, low dose local vaginal therapy may be more appropriate than systemic therapy because it concentrates the benefit on the symptomatic target while minimizing systemic exposure. This principle is also important for avoiding overtreatment. Not every patient with vaginal dryness or dyspareunia requires systemic estrogen. Conversely, in women with premature ovarian insufficiency or severe hypoestrogenism, local therapy alone is insufficient when the clinical problem includes bone, cardiovascular and systemic health. The correct choice therefore depends on which component of ovarian function is intended to be replaced.

The standard basis of ovarian hormone therapy remains the reasoned combination of systemic estrogen and progestogen protection when required. However, more advanced strategies exist and require greater clinical selection. The first is full replacement therapy in premature ovarian insufficiency, for which current recommendations emphasize that not all estrogen doses commonly used in physiological menopause are sufficient to provide true replacement. In these patients, the objective is closer to restoring lost physiology than simply controlling symptoms, which justifies the use of adequate replacement doses and particular attention to long term adherence.

A second strategy is local urogenital therapy. When vaginal dryness, burning, dyspareunia, urgency or recurrent urinary tract infections predominate in the setting of local estrogen deficiency, low dose vaginal estrogens, vaginal DHEA or other dedicated options may be preferable to systemic therapy. The selection criterion is not the potency of treatment, but its anatomical and pharmacological appropriateness. Systemic therapy may also improve genitourinary trophism, but when the problem is isolated and systemic risk does not justify exposure, local treatment represents a more targeted and rational solution.

A third area, which is widely discussed and must be handled with particular rigor, is the selective use of testosterone in women. Current consensus statements identify the treatment of hypoactive sexual desire disorder in selected women, particularly after menopause, as the only indication supported by robust evidence, following an adequate biopsychosocial assessment and exclusion of alternative relational, psychiatric, pharmacological or medical causes. Testosterone is therefore not a treatment for general wellbeing, is not a universal remedy for fatigue or low mood and should not be used on the basis of nonspecific isolated hormone measurements. When used, it requires appropriate formulations, physiological doses, monitoring of hormone concentrations and clinical signs of androgen excess and avoidance of nonstandardized compounded preparations.

In summary, advanced strategies are not shortcuts that replace standard treatment, but specialist extensions of its principles. Intensifying replacement in premature ovarian insufficiency, selecting local treatment for isolated GSM or introducing androgens in selected cases always requires precise definition of the clinical target first. Ovarian hormone therapy is most appropriate when it clearly separates what is indicated from what is merely theoretically possible.

The safety of ovarian hormone therapy depends on every component of treatment being appropriate not only in dose, but also in combination, route and duration. The first relevant iatrogenic risk is excessive estrogen exposure, which may present with breast tenderness, fluid retention, headache, nausea, bleeding instability and, in predisposed patients, increased thromboembolic or cardiovascular risk. This risk is not the same in every woman or with every route of administration. Oral therapy, for example, has a more pronounced hepatic effect, whereas the transdermal route tends to have a more favorable thrombotic profile. Safety is therefore not an abstract property of estrogen, but a property of how estrogen is administered to that particular patient.

The second crucial risk is inadequate endometrial protection. When the uterus is present, using systemic estrogen without adequate progestogen support leaves the endometrium exposed to unopposed proliferative stimulation. The effect may initially appear as spotting, endometrial thickening or bleeding instability, but the real concern is the increased long term risk of hyperplasia and endometrial carcinoma. The choice of progestogen, dose and duration of monthly exposure is therefore not an accessory detail, but a structural element of treatment safety. A regimen that appears well tolerated may still be incorrect when endometrial protection is inadequate for the estrogen load administered.

The opposite risk, namely undertreatment, must also be considered. In physiological menopause, this may mainly result in unsatisfactory symptom control, but in premature ovarian insufficiency undertreatment has greater systemic importance because it leaves bone, the cardiovascular system, sexual health and quality of life only partially protected. Poor long term adherence should also be considered a form of biological undertreatment. Failure to begin therapy when indicated, initiation that is excessively delayed or intermittent use may compromise the expected benefits just as much as a formally incorrect prescription.

Prevention of iatrogenic harm is therefore based on four steps: appropriate patient selection, choice of route and dose according to individual risk, adequate endometrial protection when required and active monitoring of bleeding and adverse events. A further methodological principle must also be applied: periodic reassessment of whether the indication remains present and whether the same treatment intensity is still required. Safety does not derive from whether a drug is hormonal or nonhormonal, but from the precision with which it is integrated into the patient’s biological timeline.

Ovarian hormone therapy produces genuine benefits only when it is followed consistently and understood by the patient. Adherence does not simply mean remembering each dose, but maintaining a coherent regimen over time, understanding why the treatment is being used, knowing the possible initial adjustments and distinguishing expected effects from warning signs that require reassessment. This is particularly important in premature ovarian insufficiency, in which treatment is often incorrectly perceived as an optional symptomatic intervention, whereas it is actually a measure of long term systemic protection. Delaying initiation or frequently discontinuing treatment reduces its benefits for bone and general health even when symptoms are modest.

Therapeutic education must explicitly clarify three points. The first is that not all hormone therapies have the same objective. Replacement therapy in a young woman is not equivalent to treatment of physiological menopause, and local vaginal therapy is not equivalent to systemic replacement. The second is that the presence of the uterus changes the structure of treatment because it requires consideration of endometrial safety, not merely symptom control. The third is that hormone replacement therapy in women with premature ovarian insufficiency is not contraceptive, so reproductive counselling must be integrated rather than assumed.

Quality of life is both an objective and an assessment tool for treatment. Hot flashes, insomnia, reduced sexual desire, vaginal dryness, pain during intercourse, fatigue, subjective cognitive decline and reduced physical and psychological wellbeing should not be dismissed, but neither should they all automatically be attributed to estrogen status. Well conducted follow up must determine when a symptom improves with therapy, when it requires adjustment and when it has a different cause that should be investigated. This prevents both underuse and overuse of hormones as an automatic response to every patient complaint.

Finally, the therapeutic alliance must include a clear definition of warning signs: persistent unexpected bleeding, the onset of a new severe headache, symptoms of thromboembolism, chest pain, marked worsening of blood pressure, signs of androgen excess when testosterone is used or persistent absence of benefit despite an apparently appropriate regimen. Well managed ovarian hormone therapy is one in which the patient understands the reason for the prescription, the clinician verifies over time that the prescription remains appropriate and the entire pathway is based not on automatic practice, but on physiology, individual risk and continuity of clinical method.